Patents Assigned to The C4
  • ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS
    Publication number: 20230190760
    Abstract: New treatments for Ikaros and/or Aiolos mediated disorders are provided that comprise administering an effective amount of a cereblon binder that degrades Ikaros or Aiolos by the ubiquitin proteasome pathway.
    Type: Application
    Filed: February 7, 2023
    Publication date: June 22, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: David Proia, James A. Henderson, Minsheng He, Andrew Charles Good, Andrew J. Phillips
  • DIHYDROQUINOLINONES FOR MEDICAL TREATMENT
    Publication number: 20230192643
    Abstract: The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Application
    Filed: August 1, 2022
    Publication date: June 22, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
  • Isoindolinone and indazole compounds for the degradation of EGFR
    Patent number: 11673902
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: June 13, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • BRAF DEGRADERS
    Publication number: 20230145336
    Abstract: Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: December 19, 2022
    Publication date: May 11, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Katrina L. Jackson, Yanke Liang, Moses Moustakim, Morgan Welzel O'Shea, Gesine Kerstin Veits, Jeremy L. Yap, Robert T. Yu, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Bernd Kuhn, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
  • ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR
    Publication number: 20230110648
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 13, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • Spirocyclic compounds
    Patent number: 11623929
    Abstract: The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 11, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Roger Norcross, Philipp Schmid
  • SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
    Publication number: 20230095223
    Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: November 11, 2021
    Publication date: March 30, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
  • TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS
    Publication number: 20230082430
    Abstract: Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.
    Type: Application
    Filed: April 18, 2022
    Publication date: March 16, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: James A. Henderson, Minsheng He, Andrew Charles Good, Andrew John Phillips
  • COMPOUNDS FOR TARGETED DEGRADATION OF BRD9
    Publication number: 20230060334
    Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.
    Type: Application
    Filed: September 1, 2022
    Publication date: March 2, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
  • Spirocyclic compounds
    Patent number: 11584748
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: February 21, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
    Publication number: 20230014124
    Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: February 1, 2021
    Publication date: January 19, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
  • HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT
    Publication number: 20230019060
    Abstract: The present invention provides heterocyclic compounds that bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation in a human or other host. The present invention also provides compounds that can be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Application
    Filed: September 2, 2021
    Publication date: January 19, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Roger Norcross, Fabian Dey, Annick Goergler, Eric Kusznir
  • Degraders and Degrons for targeted protein degradation
    Patent number: 11524949
    Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: December 13, 2022
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
  • TARGETED PROTEIN DEGRADATION
    Publication number: 20220372016
    Abstract: This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.
    Type: Application
    Filed: June 18, 2021
    Publication date: November 24, 2022
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Katrina L. Jackson, Minsheng He, Yanke Liang, Mark E. Fitzgerald, Victoria Garza
  • SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
    Publication number: 20220313827
    Abstract: This invention provides amine-linked C3-glutarimide Degronimers and Degrons for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: December 14, 2020
    Publication date: October 6, 2022
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Chi-li Chen, Martin Duplessis, Minsheng He, Kiel Lazarski
  • C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
    Publication number: 20220313826
    Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: November 30, 2020
    Publication date: October 6, 2022
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
  • N/O-linked Degrons and Degronimers for protein degradation
    Patent number: 11459335
    Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: October 4, 2022
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Martin Duplessis, Chi-Li Chen
  • DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT
    Publication number: 20220289738
    Abstract: The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
    Type: Application
    Filed: January 14, 2022
    Publication date: September 15, 2022
    Applicant: C4 Therapeutics, Inc.
    Inventors: Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
  • DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION
    Publication number: 20220251061
    Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.
    Type: Application
    Filed: May 14, 2020
    Publication date: August 11, 2022
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
  • Tricyclic degraders of Ikaros and Aiolos
    Patent number: 11407732
    Abstract: Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: August 9, 2022
    Assignee: C4 Therapeutics, Inc.
    Inventors: James A. Henderson, Minsheng He, Andrew Charles Good, Andrew John Phillips